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COMMENTARY
Sodium-glucose co-transporter 2 inhibition 
as a mitochondrial therapy for atrial fibrillation 
in patients with diabetes?
Salva R. Yurista, Herman H. W. Silljé, Michiel Rienstra, Rudolf A. de Boer and B. Daan Westenbrink*
Abstract 
While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mecha-
nistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of T2DM, particularly 
hypertension, may drive AF in the setting of T2DM. But direct mechanisms may also explain this relation, at least in 
part. In this regard, recent evidence suggests that mitochondrial dysfunction drives structural, electrical and contrac-
tile remodelling of atrial tissue in patients T2DM. Mitochondrial dysfunction may therefore be the mechanistic link 
between T2DM and AF and could also serve as a therapeutic target. An elegant series of experiments published in 
Cardiovascular Diabetology provide compelling new evidence to support this hypothesis. Using a model of high fat 
diet (HFD) and low-dose streptozotocin (STZ) injection, Shao et al. provide data that demonstrate a direct association 
between mitochondrial dysfunction and the susceptibility to develop AF. But the authors also demonstrated that the 
sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin has the capacity to restore mitochondrial function, 
ameliorate electrical and structural remodelling and prevent AF. These findings provide a new horizon in which mito-
chondrial targeted therapies could serve as a new class of antiarrhythmic drugs.
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Introduction
Type 2 diabetes mellitus (T2DM) is a major cardiovas-
cular (CV) risk factor, and its global prevalence is pre-
dicted to increase from 425 million to 600 million by the 
year 2045 [1]. The projected number of individuals with 
atrial fibrillation (AF) in the European Union could reach 
14–17 million by 2030 [2]. T2DM and AF have both 
emerged as cardiometabolic epidemics [1, 2]. Patients 
with T2D are at a 40% increased risk to develop new-
onset AF [3–5] and the risk of new-onset AF increased 
gradually with advancing diabetic stage [6]. Furthermore, 
patients with T2D and AF are also at increased risk to for 
complications of AF such as stroke and systemic embo-
lisms and hospitalisations for heart failure (HF) [7–9]. In 
addition, the evidence has suggested that these patients 
may actually benefit from the use of non-vitamin K oral 
anticoagulants (NOACs) given the demonstrated efficacy 
and improved safety profile as compared to warfarin [10]. 
This improved safety profile was also confirmed in ARIS-
TOTLE trial [11].
The mechanism responsible for the high incidence 
and increased severity of AF in patients with T2DM is 
the subject of intense speculation but remains largely 
enigmatic. Patients with AF and T2DM share common 
comorbidities such as hypertension, atherosclerosis and 
obesity [12]. Targeted therapy of risk factors has been 
shown to improve AF outcomes [13]. An observational 
cohort study from Korean National Health Insurance 
Service database suggests avoiding body weight fluctua-
tion, regardless weight gain or weight loss, is important 
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Interestingly, an experimental study by Chen et  al. 
showed that insulin resistance promotes interstitial fibro-
sis and alters calcium handling that induce arrhythmo-
genesis in the atria [16]. Morphological and functional 
comparisons of atrial tissue from patients with or without 
diabetes have revealed that fibrosis was more elevated in 
diabetic atria [17]. Furthermore, atria from patients with 
T2DM and AF consistently display evidence for increased 
oxidative stress, suggesting that the oxidative stress and/
or underlying mechanisms may represent a T2DM-spe-
cific therapeutic target for AF [18, 19].
The myocardium requires tremendous amounts of 
energy in the form of adenosine triphosphate (ATP) to 
sustain its continuous mechanical work [20]. The major-
ity of this energy is generated through oxidative phos-
phorylation in mitochondria, which comprise about 30% 
of the myocardial volume. Mitochondrial energy provi-
sion is not only essential for contraction and relaxation, 
but calcium handling by the sarcoplasmic reticulum 
and ion channel homeostasis are also critically depend-
ent on ATP availability. In addition, mitochondria also 
important myocellular storage compartments and altera-
tions in mitochondrial calcium handling contribute to 
arrhythmogenesis, pathological cardiac remodelling, and 
apoptosis. Mitochondria are also the main cardiac source 
of reactive oxygen species (ROS), which originate from 
the electron transport chain during oxidative phospho-
rylation. Under physiological conditions ROS-induced 
myocardial damage is minimized through tight control 
of the mitochondrial redox balance and an efficient and 
dynamic mitochondrial quality control program. Mito-
chondrial quality control/mitochondrial dynamics ensure 
the fitness of the mitochondrial population through con-
tinuous quality checks, the elimination of dysfunctional 
mitochondrial and promoting growth of new organelles 
[21].
In many patients with heart disease these protective 
mechanisms fall short, resulting in increases in mito-
chondrial ROS, reductions in myocardial ATP and the 
accumulation dysfunctional mitochondria. While mito-
chondrial dysfunction has been recognised as a therapeu-
tic target in other heart diseases such as heart failure, the 
role of mitochondrial dysfunction in arrhythmogenesis is 
not well described. In an elegant study published in Car-
diovascular Diabetology, Shao et al. confirm and extend 
upon previous evidence for a mechanistic link between 
T2DM, mitochondrial dysfunction and AF [22]. In addi-
tion, and rendering translational importance, the authors 
demonstrate that the sodium-glucose co-transporter 2 
inhibitors (SGLT2i) empagliflozin can reverse mitochon-
drial dysfunction and ameliorate the susceptibility to 
develop AF in rats with T2DM. Together, these findings 
indicate that mitochondrial dysfunction is a potentially 
treatable cause of AF, for which therapeutic interventions 
are already available. In the current commentary we will 
summarize contemporary evidence for the role of mito-
chondria in arrhythmogenesis in patients with AF and 
also discuss the therapeutic perspectives provided by the 
study by Shao et al. [22].
Mitochondrial dysfunction in T2DM and AF
Mitochondrial dysfunction has been described in many 
organs of patients with T2DM, including the atria [23]. 
For instance, mitochondria isolated from the atria of 
patients with diabetes display reduced mitochondrial res-
piration and increased oxidative stress, when compared 
to subjects without diabetes [24]. The mitochondrial 
architecture and the assembly of the electron transport 
chain are also altered in patients with T2DM and these 
ultrastructural changes appear to be even more pro-
nounced in the presence of AF, suggesting a reciprocal 
relation [25].
Indeed, abnormal mitochondrial structure and func-
tion have been reported in animal model of AF [26], 
Moreover, the atria of non-diabetic patients with AF 
already display enhanced mitochondrial DNA damage 
[27, 28], and reduced respiratory capacity [27, 29]. Mito-
chondrial dynamics are also altered in patients with AF, 
characterized by a reduction in mitochondrial biogenesis 
[30]. Specifically, Jeganathan et al. observed that the main 
regulator of mitochondrial biogenesis peroxisome pro-
liferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α) is downregulated in atrial tissue from patients 
with post-operative AF [30]. Furthermore, molecular 
markers for mitochondrial volume are also reduced in 
the atrial tissue from patients with AF [31]. It remains 
uncertain whether the observed mitochondrial dysfunc-
tion is a cause or a consequence of AF.
How does mitochondrial dysfunction lead to AF?
As described above, dysfunctional mitochondria are less 
able to generate ATP and produce more ROS. Excessive 
ROS production can disturb cellular electrical activity 
in two ways. First, ROS has pro-arrhythmic effects by 
modulating redox-sensitive regulatory domains of multi-
ple proteins involves in excitation contraction coupling, 
including sarcoendoplasmic reticulum (SR) calcium 
transport ATPase (SERCA),  Na+ channels,  K+ chan-
nels, L-type  Ca2+ channels (LCCs), ryanodine receptors 
(RyRs),  Na+/Ca2+ exchanger (NCX) [32–36]. In addition, 
ROS can also directly activate signalling such as  Ca2+/
calmodulin dependent kinase II (CaMKII). CaMKII is a 
multifunctional protein that serves as a nodal regulator 
of many cellular responses, including excitation–contrac-
tion coupling, excitation–metabolism coupling and exci-
tation–transcription coupling [37–40]. CaMKII can be 
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activated by multiple stimuli, including but not restricted 
to sustained increases in mitochondrial ROS and hyper-
glycaemia [37, 41]. The combination of hyperglycaemia 
and increased ROS which occurs in diabetic atria sets the 
ideal stage for robust and sustained CaMKII activation, 
which has been identified as a major driver of arrhythmo-
genicity in diabetic hearts, and may at least partially 
explain the high incidence of AF in patients with diabetes 
[41].
Bioenergetic deficiencies caused by mitochondrial dys-
function may also result in impediments in ion channels 
homeostasis. [42]. Reductions in ATP levels can lead to 
the activations of sarcoplasmic ATP-sensitive potassium 
 (KATP) channels, causing shortening of action potential 
duration (APD) and reduction of action potential ampli-
tude (APA) [43]. Furthermore, reduced mitochondrial 
ATP production suppresses the activity of SERCA and 
 Na+/K+ ATPase, which will alter calcium  (Ca2+) han-
dling [44, 45] and increase the susceptibility to develop 
AF [46].
Finally, oxidative stress and bioenergetic deficiencies 
can also promote cardiomyocyte hypertrophy and inter-
stitial fibrosis, two central drivers of atrial remodelling 
that promote AF [47]. As described above, atrial remod-
elling is a hallmark of AF and the degree of atrial remod-
elling is more pronounced in individuals with diabetes 
[48]. In summary, mitochondrial dysfunction in atria 
from diabetic subject can promote AF through multiple 
mechanisms summarized in Fig.  1. These findings sug-
gest that targeting mitochondria could represent a fea-
sible therapeutic strategy to reduce the burden of AF in 
diabetic patients.
SGLT2i are designed to reduce hyperglycaemia [49] 
but have been shown to improve mitochondrial function 
in ventricular myocardium of diabetic and non-diabetic 
animal models of heart failure [50, 51]. Dr. Shao et  al. 
tested the hypothesis that these drugs may also preserve 
mitochondrial function and reduce atrial remodelling 
in diabetic atria [22]. For this purpose, they employed a 
combination of high fat diet (HFD) and low-dose strep-
tozotocin (STZ) injection to induce T2DM in male rats. 
HFD and low-dose of STZ model has been used as a rea-
sonable animal model of T2DM. Similar to pathophysiol-
ogy in human, this model demonstrates the progression 
from insulin resistance to hypoinsulinemia and hypergly-
caemia [52].
Animals with non-fasting blood glucose levels above 
16.7  mmol/l measured 1  week after STZ injection were 
considered diabetic. Diabetic rats were then randomized 
to intragastric administration of empagliflozin (10 or 
30  mg/kg/day) or vehicle for the duration of 8  weeks. 
Rats on a normal diet that did not receive HFD or STZ 
served as controls. After 8 weeks, cardiac structure and 
function were measured by echocardiography and a Mil-
lar conductance catheter. After sacrifice, atrial tissue was 
harvested to study histological and molecular indices of 
atrial remodelling and mitochondrial dynamics. In addi-
tion, mitochondria were isolated and their respiratory 
capacity and membrane potential was probed with the 
Oroboros system. In separate series of experiments, the 
hearts were excised and retrogradely perfused using a 
Langendorff setup to test AF-susceptibility with a well-
established burst pacing protocol.
As expected, empagliflozin lowered blood glucose lev-
els and reduced body weight. Moreover, treatment with 
high dose empagliflozin prevented LA enlargement and 
reduced cardiomyocyte hypertrophy and interstitial 
fibrosis. The susceptibility to AF was also normalized 
to control levels. Empagliflozin reduced oxidative stress 
as evidenced by increased superoxide dismutase (SOD) 
activity and reduced malondialdehyde (MDA) concentra-
tions. Furthermore, the reductions in mitochondrial res-
piration and mitochondrial membrane potential which 
occurred in diabetic animals were restored to control 
levels by empagliflozin. Finally, the recovery of mitochon-
drial function by empagliflozin were accompanied by 
similar improvements in mitochondrial dynamics.
The study by Shao et al. [22] is worth noticing for sev-
eral reasons.
First, most studies with SGLT2i have focussed on 
ventricular myocardium. The current study is the first 
to show that SGLT2i prevent electrical and struc-
tural remodelling of atria and reduces the propensity 
to develop AF. It was recently shown that SGLT2i can 
improve outcome in heart failure patients with or with-
out diabetes [53]. Mitochondrial dysfunction and atrial 
remodelling are relatively independent of the presence 
of diabetes and similar mito-protective effects have been 
observed in non-diabetic models. The beneficial effects of 
SGLT2i could therefore also translate into similar generic 
benefits patients with AF. Nevertheless, it is also pos-
sible that the benefits on the atria occur via changes in 
plasma metabolites or other indirect effects. Thus, fur-
ther research is required to confirm this hypothesis.
Second, while several studies have provided suggestive 
evidence that empagliflozin improves myocardial func-
tion, the authors are the first to convincingly show that 
SGLT2i improve mitochondrial respiration at the orga-
nelle level. In addition, the authors are the first to demon-
strate that these mito-protective effects also occur in the 
atrium. In addition, the authors provide evidence that the 
favourable mitochondrial effects of SGLT2i have the pro-
pensity to reduce the burden of AF. Of note, a meta-anal-
ysis of 35 studies that included 34,987 T2DM patients 
showed no difference in AF occurrence between SGLT2i 
and placebo [54].
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Fig. 1 Contribution of diabetes to pathophysiology of atrial fibrillation. OXPHOS oxidative phosphorylation, ATP adenosine triphosphate, ROS 
reactive oxygen species, CaMKII  Ca2+/calmodulin dependent kinase II, AF atrial fibrillation. Part of illustration elements courtesy of Servier Medical 
Art
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Summary and conclusions
In summary, the present study has extended our knowl-
edge on the effects of SGLT2i and empagliflozin on atrial 
electrical and structural remodelling in diabetic setting. 
It provides compelling evidence that mitochondrial dys-
function could serve as a promising therapeutic target in 
AF, at least in diabetic patients. A proposed mechanism 
illustrating how SGLT2i could prevent AF in T2DM is 
shown in Fig.  2. Indeed, further mechanistic studies in 
both human and animals to better understand the ben-
efits and potential application are warranted. Post-hoc 
analyses of ongoing and upcoming trials may also help 
to better define the scope of clinical effects of SGLT2i in 
patients with prevalent AF and to evaluate their effects 
on new onset AF. The current analysis provides a first 
step that may lead to mitochondrial targeted therapy for 
the treatments of AF in patients with diabetes?
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